Immune-Onc Therapeutics Announces Orphan Drug Designation of IO-202 (Anti-LILRB4) for Treatment of AML and Poster Presentation at ASH 2020

PALO ALTO, Calif.--(BUSINESS WIRE)-- #AML--Immune-Onc Therapeutics Announces Orphan Drug Designation for IO-202 (anti-LILRB4) for Treatment of AML and Poster Presentation at ASH 2020

Click to view original post